As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming more common. These people are often younger women with no history of tobacco exposure. Researchers are working to understand the needs of this growing population by identifying other risk factors for lung cancer, such as family history and environmental exposures. They are also studying the molecular underpinnings of this disease to develop targeted approaches for early detection and treatment. As part of LUNGevity’s

The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In February, we welcomed Randi Williams, PhD, MPH, of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center. Her research focuses on methods to promote the adoption of evidence-based lung cancer control practices

Read time: 2 minutes. Here we present the final video in our three-part series about how patients and researchers can work together to develop clinical trials. In the video below, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to illustrate the power of having patients contribute to the research process. We use a real-world example to learn about patient-researcher collaborations through the POSITIVE study, a breast cancer-focused clinical trial. You can watch the entire video, or use the timestamps below. Make sure to watch parts 1 and 2 of this series here: How Can

Read time: 2 minutes. We are pleased to continue our three-part series about how patients and researchers can work together to develop clinical trials. In this second video, LUNGevity again partnered with Rising Tide for Clinical Cancer Research to show how researchers and patient advocates can be empowered with tools to create clinical trials that resonate with patients and address the key issues they care about. If you missed the first video, How Can Patients and Researchers Design Clinical Trials Together, you can watch it here. Watch Part 2 below, or use the timestamps to skip to a

Read time: 3 minutes. Throughout 2024 we published blogs sharing scientific meeting recaps, educational content, personal stories, treatment news, and so much more. Below are the most popular articles we published in 2024. If you’re looking for survivor features and personal stories, you can see all the lung cancer survivors we highlighted in 2024 right here. 2024 ASCO: Highlights of Lung Cancer Research In June, we recapped the annual American Society of Clinical Oncology meeting. Thousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates

LUNGevity had a tremendous year supporting impactful research in 2024. In addition to our existing portfolio of ongoing research grants, we issued several new research awards in 2024. All of these awards are in strategic areas of research that are likely to move the dial for people living with lung cancer today and those who will be diagnosed in the future. Below are more details about the research projects we recently announced funding for. LUNGevity Supports 10 New Research Projects Totaling $3,141,656 In 2024 Early Detection LUNGevity and our partner, Rising Tide for Clinical Cancer

Read time: 5 minutes. This year marks 20 years since researchers made a key discovery that changed the face of lung cancer research and treatment. By uncovering EGFR’s role in lung cancer, researchers developed a new class of drugs—targeted therapies—designed to target specific mutations in lung cancer cells while leaving healthy cells unharmed. As we’ve welcomed this era of precision medicine, we’ve also benefited from other treatment progress in lung cancer—including the development of effective immunotherapies. During LUNGevity’s 2024 International Lung Cancer Survivorship Conference (ILCSC

Lung cancer screening and early detection were major topics of discussion at the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical Oncology (ESMO) conference in Barcelona from September 13-17. This fourth and final blog in our series of updates summarizes highlights from these discussions. You can read the other update blogs from these fall science meetings: Metastatic NSCLC Highlights Small Cell Lung Cancer Highlights Early-Stage and Locally Advanced NSCLC Cancer screening involves tests that can detect early-stage cancer when

Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug Development? Part 2: How We Define Success for a Clinical Trial The United States federal government aims to regulate prescription drugs to ensure people are receiving medication that’s safe and effective. Every prescribed drug in the U.S. has gone through a rigorous testing process that can take over a decade to complete before the U.S. Food and Drug Administration (FDA) approves the drug and people can benefit from

Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development. We all want a treatment for lung cancer that is completely safe and entirely effective. While researchers are working toward that goal, the reality is we aren’t there yet. Every treatment we are considering comes with potential benefits and side effects. The overarching role of clinical trials is to measure the pros and cons of each drug to help us identify the best treatments for